Earnings Call · Q1 FY2024·2024-05-09

Q1 24EPS +10.10%·Rev n/aQ4 23EPS -4.76%·Rev n/aQ3 23EPS -18.75%·Rev n/aQ2 23EPS -22.73%·Rev n/a⚠ consensus missing

NEKTAR THERAPEUTICS NKTR

Vivian Wu — Investor Relations or Communications

Howard W. Robin — President and Chief Executive Officer

Jonathan Zalevsky — Chief Research and Development Officer

Jennifer Ruddock — Chief Financial Officer

−2.4%1d on move date−3.0% vs SPY3d+6.7%5d+11.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NKTR calls or request research access.

More NKTR calls Browse calls Request research access